(ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study

Category Primary study
ConferenceSociety of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer
Year 2025
This article has no abstract
Epistemonikos ID: e6618315fd37ae25cd5babac2b684af80878c210
First added on: Oct 17, 2025